Focus on specific regions of interest using hybridization-based target enrichment
Next-generation sequencing (NGS), with its ability to process hundreds of millions of DNA templates in parallel, has increased sequencing throughput and diminished sequencing costs tremendously1. However, whole genome sequencing is still expensive and does not provide the precision and depth of information required to decipher the roles of individual genes in complex diseases or afford the ability to investigate rare and low-frequency genetic variants. A more cost-effective way is to focus on specific regions of interest using target enrichment strategies. Target enrichment allows focusing of sequencing resources, which leads to reduced cost and simplified analysis2.
KAPA Target Enrichment Portfolio
Combining more than a decade of design experience with an improved manufacturing technology, the KAPA Target Enrichment Portfolio unlocks the potential of your starting material to bring you the answers you seek.
Superior capture uniformity for lower sequencing costs/time
Demonstrated design expertise for targeting difficult-to-capture sequences
Outstanding single-vendor support across the entire workflow
Monitor the sequence of the SARS-CoV-2 virus and the emergence of new variants with the KAPA SARS-CoV-2 Target Enrichment Panel. This panel targets 100% of the reference SARS-CoV-2 genome (NC_045512) and >99.7% of another 183 publicly available SARS-CoV-2 genomes (GenBank).
KAPA HyperChoice Probes (for human designs) and KAPA HyperExplore Probes (for
nonhuman designs) are fully customizable target enrichment panels for hybridization-based capture before next-generation sequencing.
Design Custom NGS Target Enrichment Panels with Ease
HyperDesign is a new online tool that uses Roche’s renowned algorithm for probe design and selection, enabling you to customize your target enrichment panels to meet the unique needs of your research. In addition, Roche’s Support Scientists are ready to help you with design planning and optimization.
Our SeqCap Target Enrichment portfolio has been discontinued. If you are an existing SeqCap user and need support, please contact our Scientific Support team for all your inquiries.